These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2053 related articles for article (PubMed ID: 33568498)

  • 1. Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
    Ma C; Wang J
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33568498
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.
    Li Z; Lin Y; Huang YY; Liu R; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33568500
    [No Abstract]   [Full Text] [Related]  

  • 3. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Copertino DC; Duarte RRR; Powell TR; de Mulder Rougvie M; Nixon DF
    J Med Virol; 2021 Jan; 93(1):187-189. PubMed ID: 32658304
    [No Abstract]   [Full Text] [Related]  

  • 4. Montelukast and Coronavirus Disease 2019: A Scoping Review.
    Sharifinejad N; Sharafian S; Salekmoghadam S; Tavakol M; Qorbani M
    Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):384-393. PubMed ID: 34418892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator.
    Chen Y; Wang X; Shi H; Zou P
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.
    Bhattacharyya D
    Med Hypotheses; 2020 Nov; 144():110046. PubMed ID: 33254480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. As a potential treatment of COVID-19: Montelukast.
    Fidan C; Aydoğdu A
    Med Hypotheses; 2020 Sep; 142():109828. PubMed ID: 32416408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies.
    Durdagi S; Avsar T; Orhan MD; Serhatli M; Balcioglu BK; Ozturk HU; Kayabolen A; Cetin Y; Aydinlik S; Bagci-Onder T; Tekin S; Demirci H; Guzel M; Akdemir A; Calis S; Oktay L; Tolu I; Butun YE; Erdemoglu E; Olkan A; Tokay N; Işık Ş; Ozcan A; Acar E; Buyukkilic S; Yumak Y
    Mol Ther; 2022 Feb; 30(2):963-974. PubMed ID: 34678509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19.
    Kerget B; Kerget F; Aydın M; Karaşahin Ö
    J Med Virol; 2022 May; 94(5):1950-1958. PubMed ID: 34958142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Montelukast in children with allergic rhinitis amid COVID-19 pandemic.
    Kow CS; Hasan SS
    Acta Paediatr; 2020 Oct; 109(10):2151. PubMed ID: 32686128
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.
    Al-Kuraishy HM; Al-Gareeb AI; Almulaiky YQ; Cruz-Martins N; El-Saber Batiha G
    Eur J Pharmacol; 2021 Aug; 904():174196. PubMed ID: 34004207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays.
    Ma C; Tan H; Choza J; Wang Y; Wang J
    Acta Pharm Sin B; 2022 Apr; 12(4):1636-1651. PubMed ID: 34745850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol.
    Mera-Cordero F; Bonet-Monne S; Almeda-Ortega J; García-Sangenís A; Cunillera-Puèrtolas O; Contreras-Martos S; Alvarez-Muñoz G; Monfà R; Balanzo-Joué M; Morros R; Salvador-Gonzalez B
    Trials; 2022 Jan; 23(1):19. PubMed ID: 34991703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Montelukast in hospitalized patients diagnosed with COVID-19.
    Khan AR; Misdary C; Yegya-Raman N; Kim S; Narayanan N; Siddiqui S; Salgame P; Radbel J; Groote F; Michel C; Mehnert J; Hernandez C; Braciale T; Malhotra J; Gentile MA; Jabbour SK
    J Asthma; 2022 Apr; 59(4):780-786. PubMed ID: 33577360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
    Dey M; Singh RK
    Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
    Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levocetirizine and montelukast in the COVID-19 treatment paradigm.
    May BC; Gallivan KH
    Int Immunopharmacol; 2022 Feb; 103():108412. PubMed ID: 34942461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Assessment-Based Enhanced Analytical Quality-by-Design Approach to Eco-Friendly and Economical Multicomponent Spectrophotometric Methods for Simultaneous Estimation of Montelukast Sodium and Bilastine.
    Prajapati P; Tamboli J; Surati P; Mishra A
    J AOAC Int; 2021 Sep; 104(5):1453-1463. PubMed ID: 34240184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Montelukast's ability to fight COVID-19 infection.
    Bozek A; Winterstein J
    J Asthma; 2021 Oct; 58(10):1348-1349. PubMed ID: 32586154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 103.